{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:59:16Z","timestamp":1792803556616,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.annonc.2020.05.018","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T01:48:37Z","timestamp":1590371317000},"page":"1169-1177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial"],"prefix":"10.1016","volume":"31","author":[{"given":"A.","family":"Demols","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Borbath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Van den Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Houbiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marechal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Delaunoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Goemine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Holbrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Van Laethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.05.018_bib1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.05.018_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2020.05.018_bib3","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.05.018_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.018_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.05.018_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, prospective, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.05.018_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.05.018_bib9","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.05.018_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2020.05.018_bib11","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","article-title":"Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model","volume":"12","author":"Abou-Elkacem","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2020.05.018_bib12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.annonc.2020.05.018_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MOG.0b013e32834405c3","article-title":"Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma","volume":"27","author":"Sirica","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.annonc.2020.05.018_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/00000478-199908000-00006","article-title":"The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of \u2018scirrhous-type\u2019 and \u2018nonscirrhous-type\u2019 growth","volume":"23","author":"Kajiyama","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annonc.2020.05.018_bib15","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bcp.2006.12.031","article-title":"Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma","volume":"73","author":"Huether","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.annonc.2020.05.018_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.05.018_bib17","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.annonc.2020.05.018_bib18","doi-asserted-by":"crossref","first-page":"107096","DOI":"10.18632\/oncotarget.22334","article-title":"Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma","volume":"8","author":"Kissel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2020.05.018_bib19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A\u00a0phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2020.05.018_bib20","article-title":"Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers","volume":"36","author":"Kim","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.05.018_bib21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.05.018_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomized phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.05.018_bib23","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.3892\/ol.2017.5847","article-title":"A\u00a0single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma","volume":"13","author":"Pan","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.annonc.2020.05.018_bib24","doi-asserted-by":"crossref","first-page":"17246","DOI":"10.18632\/oncotarget.12825","article-title":"Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study","volume":"8","author":"Luo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2020.05.018_bib25","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A\u00a0phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.05.018_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.05.018_bib27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/cas.13582","article-title":"Molecular genomic landscapes of hepatobiliary cancer","volume":"109","author":"Shibata","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.annonc.2020.05.018_bib28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast-growth factor receptor 2 translocations in intra-hepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"issue":"suppl","key":"10.1016\/j.annonc.2020.05.018_bib29","volume":"37","author":"Lamarca","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.annonc.2020.05.018_bib30","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2019.37.15_suppl.2522","article-title":"Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)","volume":"37","author":"Fukuoka","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420398392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420398392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:57:09Z","timestamp":1760335029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420398392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0923753420398392"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.018","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}